GAMIDA CELL LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0184 USD | +2.22% |
|
+6.36% | -95.54% |
| Apr. 10 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
| Apr. 05 | Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index | CI |
ETFs positioned on Gamida Cell Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.0184
USD
Average target price
6
USD
Spread / Average Target
+32,508.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -95.54% | 2.83M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- GMDA Stock
- Funds and ETFs Gamida Cell Ltd.
